Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Psoriasis market

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Breakdown of use of various therapeutic modalities in patients with psoriasis depending on the disease severity.
Figure 2: 2008 sales of selected psoriasis drugs.

References

  1. Menter, A. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J. Am. Acad. Derm. 58, 826–850 (2008).

    Article  Google Scholar 

  2. Rozenblit, M. & Lebwohl, M. New biologics for psoriasis and psoriatic arthritis. Derm. Therapy. 22, 56–60 (2009).

    Article  Google Scholar 

  3. Reich, K. et al. Ustekinumab. Nature Rev. Drug Discov. 8, 355–356 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Related links

Related links

FURTHER INFORMATION

Clinical trials.gov

The National Psoriasis Foundation

Rights and permissions

Reprints and permissions

About this article

Cite this article

Melnikova, I. Psoriasis market. Nat Rev Drug Discov 8, 767–768 (2009). https://doi.org/10.1038/nrd2996

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2996

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing